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ABSTRACT 
Conventional practice within the United Kingdom and beyond is to conduct economic 
evaluations with ‘health’ as evaluative space and ‘health maximisation’ as the decision 
making rule.  However, there is increasing recognition that this evaluative framework 
may not always be appropriate, and this is particularly the case within public health and 
social care contexts.  This paper presents a methodological case study designed to 
explore the impact of changing the evaluative space within an economic evaluation from 
health to capability wellbeing and the decision making rule from health maximisation to 
the maximisation of sufficient capability.  Capability wellbeing is an evaluative space 
grounded on Amartya Sen’s capability approach and assesses wellbeing based on 
individuals’ ability to do and be the things they value in life.  Sufficient capability is an 
egalitarian approach to decision making that aims to ensure everyone in society 
achieves a normatively sufficient level of capability wellbeing.  The case study is 
treatment for drug addiction and the cost-effectiveness of two psychological 
interventions relative to usual care is assessed using data from a pilot trial.  Analyses 
are undertaken from a health care and a government perspective.  For the purpose of 
the study, Quality-Adjusted Life-Years measured using the EQ-5D-5L, Years of Full 
Capability equivalent and Years of Sufficient Capability equivalent, both measured using 
the ICECAP-A, are estimated. The study concludes that different evaluative spaces and 
decision making rules have the potential to offer opposing treatment recommendations.  
The implications for policy makers are discussed.  
Keywords: economic evaluation; wellbeing; ICECAP; health maximisation; capability 
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INTRODUCTION 
Health economic evaluations predominantly adopt an extra-welfarist approach, aiming 
to maximise health in a resource constrained environment.  This approach is advocated 
by all national health technology assessment bodies that use economic evaluation to 
inform decision making, such as the UK National Institute for Health and Care 
Excellence, the Dutch National Health Care Institute, the Canadian Agency for Drugs and 
Technologies in Health, and the Australian Pharmaceutical Benefits Advisory Committee 
[1].  Although national submission guidelines may differ on whether health care costs, 
with or without personal social services costs, or broader societal costs should be 
included in economic analyses, they all advocate the maximisation of health, using 
Quality-Adjusted Life-Years (QALYs) as the standard unit of outcome.  This approach to 
economic evaluation and resource allocation may be appropriate for the assessment of 
health care technologies or services that have cost and outcomes that fit neatly within 
the health sector, but there is a burgeoning literature outlining the reasons why ‘health’ 
as evaluative space and ‘health maximisation’ as the decision making rule might not be 
appropriate at least in some circumstances [2-10].   
The realisation that the conventional toolbox for health economic evaluations might not 
be appropriate where interventions have spill-over effects on family members or 
informal carers [3], where interventions are aimed at the community rather than 
individuals [4-6], and where interventions lead to an improvement in outcomes that go 
beyond the traditional health focus [7-10] has led to an increased interest in how to 
adapt methods for capturing broader evaluative spaces.  A major contribution in this 
direction has been the development of a number of capability instruments, including 
ASCOT [11], OxCap-MH [12], and the ICECAP measures [13-15].  The ICECAP measures 
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are intended to provide a generic measure for use in economic evaluations, while 
ASCOT and OxCap-MH were developed for application in social care and mental health 
respectively.  These outcome measures have all been developed on the theoretical 
foundations set out by Amartya Sen’s capability approach to human wellbeing [16], and 
aim to offer an alternative and broader evaluative space with a focus on people’s 
capability to function in terms of their wider wellbeing (capability wellbeing) rather 
than their actual functioning in terms of health only.   
A recently published study looked at the relative impacts of a number of common health 
conditions on health and capability wellbeing [17].  It concluded that changing the 
evaluative space from a health-focused metric, such as the EQ-5D-5L, to one focused on 
capability wellbeing, such as the ICECAP measure for adults (ICECAP-A), could have a 
significant impact on funding priorities, and this was likely to positively affect the case 
for mental health conditions.  The work also showed that the choice of evaluative space 
for economic evaluation is an important value judgement that can have a large impact 
on resource allocation decisions.   
Evidence that capability wellbeing can potentially offer a more suitable evaluative space 
than health in certain contexts continues to emerge.  A study has just been published 
showing that capability wellbeing, measured using the ICECAP-A, can incorporate into 
economic evaluations broader wellbeing impacts of addiction treatments that may be 
missed within the evaluative space of health, measured using the EQ-5D-5L [18].  
Having close people to discuss personal issues and socialise with, and having personal 
self-esteem, were some of the broader determinants of capability wellbeing that were 
missed within the evaluative space of health.  This study concluded that the ICECAP-A 
was at least as sensitive in capturing impacts on health-related clinical indicators as the 
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EQ-5D-5L and significantly more sensitive for clinical indicators of broader wellbeing, 
advocating capability wellbeing as a more suitable evaluative space for substance use 
disorder treatments [18].  
Apart from the choice of evaluative space, the choice of health maximisation is another 
value judgment that may have a large impact on the way resources are allocated.  The 
maximisation of health is only one approach to decision making and evidence shows 
that society might value different approaches more highly [19-24].  It is this thinking 
that has led some health economists to move away from this conventional approach of 
health maximisation and to explore alternative more ‘egalitarian’ approaches that give a 
greater allowance to distributional concerns [25-29].  One such approach, which was 
influenced by Rawls’s theory of justice [30] and can be traced as far back as 1985 [31], is 
aiming to bring the members of society to a ‘sufficient’ threshold level of health.   
Notions of sufficiency have also been advocated within the capability approach [32].  A 
recently published literature review highlighted that the sufficiency goal was more 
commonly encountered in the capabilities literature than maximisation [33], and 
indeed, sufficiency is closely related to the equality in the space of capabilities that 
Amartya Sen advocated [34].  A method for incorporating this within an economic 
evaluation framework has recently been developed [35].  This ‘Sufficient Capability’ 
approach prioritises individuals below a normatively sufficient level of capability and 
aims to maximise the number of people in society that achieve sufficient capability [35].   
A clinical area where broader evaluative spaces and egalitarian rules for decision 
making may be more pertinent to clinical and policy objectives is drug addiction [36, 
37].  In this context, clinical and policy objectives are about achieving a broader notion 
of wellbeing from multifaceted psychosocial approaches that aim to ‘nudge’ clients into 
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making better choices, and broader measurable effects on the physical and mental 
health of user’s family and friends are commonly evident [38, 39].  This paper is building 
on a previous study that found important differences in the psychometric performance 
of the ICECAP-A and EQ-5D-5L in drug dependency [18], and aims to explore whether 
different evaluative spaces and decision making rules in economic evaluations based on 
the capability approach have the potential to impact on treatment recommendation.  
The economic evaluation of two active psychological interventions offered in addition to 
standard care for heroin users in opioid substitution treatment is used as a case study. 
 
METHODS 
Trial design and participants 
Detailed information about the study design and participants can be found elsewhere 
[40].  In brief, this was a pilot study with a pragmatic, multicentre, randomised parallel 
group design comparing two active psychological interventions, offered as adjunct to 
usual care, with usual care.  Clients who had been receiving opioid substitution 
treatment for more than 12 months but still reported opiate use in the preceding 28 
days were recruited.  This represented a population that had failed to receive maximum 
benefit from standard treatment.  All participants provided written informed consent 
and were followed-up for 12 months.  Ethical approval was received from the National 
Research Ethics Committee [REC Ref: 12/WM/0046].  Information about the three 
interventions is presented below. 
1.  Treatment as usual (TAU):  Participants received methadone or 
buprenorphine in addition to an individual session with a drug worker every 1-2 
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weeks covering topics related to case management, signposting of other services, 
structured psychosocial interventions, and other activities (e.g. medication 
issues). 
2.  Brief Social Behaviour and Network Therapy (B-SBNT) + TAU:  B-SBNT 
therapy was delivered according to a purpose-designed manual.  Clients were 
invited to attend four 50-minute B-SBNT sessions over a period of 6 weeks in 
addition to medication and TAU sessions as described above.  The aim was to 
assess the participant’s social support network, and to involve key members in 
helping them attain personal goals [41]. 
3.  Personal Goal Setting (GS) + TAU:  GS involved an additional active component 
to usual care through a structured process of setting personal goals and 
monitoring their attainment, and was delivered according to a purpose-designed 
manual.  Participants were expected to attend four 50-minute sessions over a 
period of 6 weeks in addition to receiving medication and TAU as above. 
 
Resource use and costs 
Resource use information was collected using the Client Service Receipt Inventory [42].  
The resource use questionnaire was administered during face-to-face interviews at 
baseline, 3 months, and 12 months post-randomisation, with participants having to 
recall resource use ‘over the last 3 months’.  In order to avoid a high drop-out rate 
associated with multiple follow-up periods in this clinical context, while still assessing 
the short and long-term impact of interventions, intermediate follow-up periods were 
not included within the trial.  
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Resource use was collected from both a national health service and personal social 
services (NHS/PSS) perspective and a government perspective.  For pragmatic reasons 
discussed at the end of the manuscript, resource use associated with a societal 
perspective, such as out-of-pocket expenditure, was not collected.  Unit costs for health 
and social care services were obtained from national sources [43-45], and are shown in 
Table 1.  Unit costs of criminal justice services and social security benefits came from 
government sources [46-50], and are detailed in Table 2.  As supported living costs are 
funded by the state [51] these were included in the analysis (Table 2) [52, 53].  
Medication costs were calculated according to patient-specific dosage and frequency, 
and unit costs were obtained from the British National Formulary [54]. 
(Tables 1 and 2 about here) 
Costs related to the training of therapists and the delivery of interventions were 
calculated using a standard micro-costing approach [55].  The time supervisors and 
therapists spent in training, supervision and delivery of interventions were valued using 
salary information [44, 56, 57], and the total staff training costs for each intervention 
were spread across the number of participants in each trial-arm.  To incorporate the 
opportunity cost of staff time for each missed appointment, a conservative estimate of 5 
minutes of therapists’ time was assumed in cases where participants did not attend a 
session [58].  All unit costs were evaluated in UK pounds sterling at a 2012/13 price 
base.  Given that baseline costs were likely to be predictors of follow-up costs, 
differences in total costs between trial-arms were adjusted for variations in the costs 
occurring during the 3 months prior to baseline [59]. 
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Outcome measures 
In line with the conventional health care decision making principle of outcome 
maximisation described earlier, two units of outcome were estimated for the analysis. 
The first outcome is QALYs, estimated based on participants’ responses to the EQ-5D-5L 
[60].  The EQ-5D-5L is a measure used to capture the evaluative space of health through 
the dimensions of mobility, self-care, usual activities, pain and discomfort, and anxiety 
and depression, with each dimension having five possible levels of health.  Individual 
response permutations to the EQ-5D-5L were used to calculate health index scores 
based on the UK crosswalk value set [61].  This value set was developed by mapping 
responses to the EQ-5D-5L measure to the UK value set developed for the EQ-5D-3L 
using the time trade-off method [62]. 
The second outcome is Years of Full Capability equivalent (YFC), which means that a 
gain of one year in full capability is the equivalent to a shift from one year with no 
capability to a year with full capability.  YFC were estimated based on participants’ 
responses to the ICECAP-A measure [14].  The ICECAP-A is a measure used to capture 
the evaluative space of capability wellbeing through the dimensions of stability, 
attachment, autonomy, achievement, and enjoyment, with each dimension having four 
possible levels of capability.  The ICECAP-A measure is shown in Appendix 1.  Response 
permutations to the ICECAP-A were translated into capability index scores based on the 
UK population value set developed using the best-worst scaling method [63].  Capability 
index scores are anchored at full capability and no capability.  They are, therefore, 
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conceptually different from health index scores, which are anchored at full or perfect 
health and death.  In terms of dealing with death within the capability wellbeing 
approach, it is important to acknowledge the philosophical assumption that a year of 
death would be seen as conceptually equivalent to a year of no capability. 
To explore an alternative decision making rule that is focused on everyone achieving a 
sufficient level of capability, Years of Sufficient Capability equivalent (YSC) were 
estimated based on individual responses to the ICECAP-A measure.  The difference 
between YFC and YSC is that full capability (i.e. scoring of 44444) is substituted with 
sufficient capability (e.g. scoring of 33333).  The methodology for setting a sufficient 
capability threshold is described elsewhere [35], and involves an adjustment to the 
ICECAP-A value set in a way that improves the relative value of capability wellbeing 
states below a stated threshold of sufficient capability.  For the purposes of this study, 
the sufficient capability threshold was set where individuals had at least ‘a lot’ of 
capability on all attributes of the ICECAP-A (i.e. scoring of 33333).  QALYs, YFC and YSC 
were estimated using the standard area under the curve approach [55], whereby 
quantity of time is adjusted for health-related quality of life, in the case of QALYs, and 
for full or sufficient capability, in the case of YFC or YSC respectively.  Given that QALYs 
are influenced by baseline health-related quality of life [64], and the calculation of YFC 
and YSC is underpinned by the same principles as QALYs, differences in mean outcomes 
between trial-arms were adjusted for baseline imbalances in the respective health or 
capability index score.  Both the EQ-5D-5L and the ICECAP-A were administered at 
baseline, 3 months, and 12 months post-randomisation.   
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Missing data 
Logistic regressions and t-tests were used to explore whether missingness for cost and 
outcome variables could be predicted by other variables in the dataset.  In the absence 
of statistically significant associations at the 5% level, data were assumed to be missing 
completely at random.  To avoid, however, any loss of efficiency or potential bias of the 
results with the exclusion of participants with missing data [65, 66], multiple 
imputation for cost components [67], health, capability and sufficient capability index 
scores [68] was performed using chained equations with predictive mean matching 
[69].  In addition to including the treatment group, covariates for each imputed variable 
were selected separately with stepwise regressions from baseline health or capability, 
age, gender, receiving state benefits, employment status, type of accommodation, 
contacts to the criminal justice services and length of time in treatment.  Ten different 
imputed datasets were developed. 
 
Cost-effectiveness analysis 
Economic analyses were conducted on an intention-to-treat basis. A time-horizon of one 
year was used and thus, costs and outcomes were not discounted.  The study conducted 
the following explorations:  
1.  Exploring the impact of a broader costing perspective on treatment 
recommendation (moving from a NHS/PSS perspective to a government 
perspective);  
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2.  Exploring the impact of a broader evaluative space on treatment 
recommendation (moving from QALYs to YFC within a NHS/PSS perspective); 
3.  Exploring the impact of both broader costing perspective and broader 
evaluative space on treatment recommendation (moving from QALYs to YFC 
within a government perspective);  
4.  Exploring the impact of a different decision making rule on treatment 
recommendation (moving from QALYs and YFC to YSC within a NHS/PSS and a 
government perspective). 
For the purposes of this study, the cost-effectiveness analysis concentrated on the 
economic evaluation of the long-term impact of interventions, incorporating all cost and 
outcome data collected as part of the trial.  Differences in the mean cost and mean 
outcomes between trial-arms and 95% confidence intervals (CIs) from the 10 multiply 
imputed datasets were obtained according to Rubin’s rules [70].  Due to the presence of 
influential observations in a modest sample size, standard methods for estimating 
differences in costs and outcomes (OLS-based multiple regression) and surrounding 
uncertainty (BCa bootstrapping) could lead to misleading inferences [71, 72] and so a 
robust regression analysis using iteratively reweighted least squares was performed 
[73].  The cost-effectiveness was evaluated by comparing the costs and outcomes of the 
three interventions using incremental cost-effectiveness ratios (ICERs) as appropriate 
[55, 74].   
Non-parametric bootstrapping with robust regression was used to generate a joint 
distribution of incremental mean costs and mean outcomes for the interventions 
compared [75, 76].  The 5,000 paired estimates produced from the bootstrapping of 
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each multiply imputed dataset were then used to calculate the probability of each 
intervention being cost-effective at different threshold values of willingness to pay 
(WTP) per additional unit of outcome, which was subsequently estimated across the 
imputed datasets based on Rubin’s approach.  This information was used to derive cost-
effectiveness acceptability frontiers (CEAFs), which reflect the uncertainty around the a 
priori decisions [77, 78].   
 
RESULTS 
Participants 
In total, 83 patients, with a mean age of 37 years (SD = 6.5), were recruited and 
randomised to TAU (n = 30), GS (n = 27) and B-SBNT (n = 26).  Most participants were 
male (86.8%), single (90.4%), of white ethnicity (84.3%), and were receiving opioid 
substitution treatment for more than five years (80%).  Participants were mostly living 
in an owned or rented accommodation (90.4%), with 3 (3.6%) participants living in a 
hostel and 5 (6%) being homeless, were unemployed (76%), and were receiving state 
benefits (82%).  Post-randomisation, 5 (6%) participants were lost to follow-up.  
Missing cost and outcome data existed for another 4 (4.8%) and 8 (9.6%) participants at 
3 and 12 months follow-up.  Consequently, missing data for 9 (10.8%) and 13 (15.6%) 
participants at the two follow-up periods were imputed. 
 
 
Resource use and costs 
14 
 
The most frequent contacts with health and social care services were with a drug team 
(97% of the sample), community pharmacists (93%), general practitioners, either as a 
face-to-face contact (48%) or telephone contact (37%), and other drug-related services 
(18%).  Approximately 15% of participants reported a contact with the criminal justice 
system.  A breakdown of the mean total per-client costs is presented in Table 3.  
Primary care, medication and community care in particular were the most substantial 
cost components from a NHS/PSS perspective, while state benefits and criminal justice 
contacts were the most significant additional cost components from a government 
perspective.  As shown in Table 3, at 12 months follow-up, B-SBNT was found to be 
£420 (95% CIs: -£334 to £1,175) more expensive than TAU from a NHS/PSS perspective 
and £443 (95% CIs: -£1,044 to £1,931) from a government perspective.  On the 
contrary, compared to TAU, GS was cheaper by £198 (95% CIs: -£955 to £559) and 
£405 (95% CIs: -£1,905 to £1,094) from a NHS/PSS and a government perspective, 
respectively.  Differences in treatment cost from either perspective were not 
statistically significant. 
(Table 3 about here) 
 
Outcome measures 
Mean per-client outcomes for the three interventions at baseline and 12 months follow-
up are presented in Table 4.  At baseline, imbalances between trial-arms for all 
outcomes were evident and therefore all incremental analyses were adjusted for 
baseline differences.  At 12 months post-randomisation, GS was the most effective 
intervention in terms of QALYs with a difference of 0.037 (95% CIs: -0.059 to 0.133) 
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compared with TAU.  In terms of YFC and YSC, TAU was the most effective intervention 
with B-SBNT being -0.038 (95% CIs: -0.117 to 0.041) and -0.028 (95% CIs: -0.110 to 
0.054) less effective compared with TAU in the two outcome measures, and with GS 
being -0.017 (95% CIs: -0.091 to 0.056) and -0.010 (95% CIs: -0.088 to 0.067) less 
effective compared with TAU in the two outcome measures. 
(Table 4 about here) 
 
Cost-effectiveness analysis  
1. Exploring the impact of a broader costing perspective on treatment 
recommendation (moving from a NHS/PSS perspective to a government 
perspective) 
With health as an evaluative space, GS was found to be the cheapest intervention and 
the one that produced the greatest QALY gain.  In cost-effectiveness terms, GS 
dominated the other two interventions.  As shown in the CEAF of Figure 1, at the 
conventional threshold level of £20,000 per additional QALY [79], GS had a 77% 
probability of being cost-effective.  Taking a government perspective, with the inclusion 
of additional costs related to accommodation, state benefits and the criminal justice 
system, did not change this result.  GS remained the dominant strategy with a 78% 
probability of being cost-effective at the same threshold level of WTP per additional 
QALY. 
(Figure 1 about here) 
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2. Exploring the impact of a broader evaluative space on treatment recommendation 
(moving from QALYs to YFC within a NHS/PSS perspective) 
With capability wellbeing as an evaluative space, GS and B-SBNT produced 0.017 (95% 
CIs: -0.091 to 0.056) and 0.038 (95% CIs: -0.117 to 0.041) less YFC compared with TAU 
respectively.  B-SBNT was also £420 (95% CIs: -£334 to £1,175) more expensive 
compared with TAU from a NHS/PSS perspective, and therefore was dominated by the 
other two interventions.  GS produced a more ‘unusual’ cost-effectiveness result as it 
was £198 (95% CIs: -£955 to £559) cheaper than TAU from the same costing 
perspective.  This meant that GS produced cost-savings for a small reduction in 
outcome.  The optimal strategy under this scenario depends on decision makers’ 
willingness to offset outcome to make cost-savings.  For a WTP above £11,500 per 
additional YFC, TAU was the optimal intervention with a probability of being cost-
effective ranging between 50% and 60% as the WTP increased (Figure 2).   
(Figure 2 about here) 
 
3. Exploring the impact of both broader costing perspective and broader evaluative 
space on treatment recommendation (moving from QALYs and YFC within a 
government perspective) 
From a wider government perspective and capability wellbeing as an evaluative space, 
if decision makers were willing to pay more than £23,500 per additional YFC, TAU 
would be the optimal intervention with a probability of being cost-effective ranging 
between 43% and 57% as the WTP threshold increased (Figure 3).  If decision makers’ 
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WTP per additional YFC was below £23,500, GS would be the optimal intervention with 
more than 51% probability of being cost-effective. 
(Figure 3 about here) 
 
4. Exploring the impact of a different decision making rule on treatment 
recommendation (moving from QALYs and YFC to YSC within a NHS/PSS and a 
government perspective) 
Changing the decision rule from health and full capability maximisation to the 
maximisation of sufficient capability, with the use of  YSC as the outcome of the 
economic evaluation, showed that GS and B-SBNT produced 0.010 (95% CIs: -0.088 to 
0.067) and 0.028 (95% CIs: -0.110 to 0.054) less YSC compared with TAU, respectively.  
B-SBNT was also more expensive than TAU from both an NHS/PSS and government 
perspective and, therefore, was dominated.  GS was cheaper from both costing 
perspectives and thus, similar to the YFC, would require decision makers’ to make a 
judgement about how many YSC would be willing to forego to make a cost-saving.   If 
decision makers were willing to pay above £19,700 per YSC from a NHS/PSS 
perspective and above £40,200 from a government perspective, then TAU would be the 
optimal strategy with the probability of being cost-effective being nearly 50% for both 
perspectives (Figure 4). 
(Figure 4 about here) 
 
DISCUSSION 
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Several studies have raised the importance of using broader costing perspectives in the 
economic analysis of treatments for drug addiction, as substantial costs are incurred by 
different government bodies [80-83].  Except for these intersectoral costs, interventions 
are also likely to generate benefits that extend beyond the health domain of the client 
and impact on wider personal and interpersonal wellbeing.  The National Institute for 
Health and Care Excellence in the UK has recently acknowledged that broader 
preference-weighted measures of social care outcomes or capability wellbeing may be 
more appropriate in the economic evaluation of social care interventions [84].  
Nevertheless the empirical analysis of these broader evaluative spaces remains an 
underexplored area in health economics [4].   
This paper conducted an economic evaluation of drug addiction treatments and 
explored the impact that broader evaluative spaces and costing perspectives as well as 
different rules for decision making may have on treatment recommendations.  A 
summary of the results and subsequent treatment recommendations are provided in 
Table 5.  From a NHS/PSS perspective, using QALYs as the unit of outcome, GS 
dominated all other treatment options.  Broadening the perspective for costs did not 
alter this treatment recommendation.  Therefore, using a conventional application of 
economic evaluation (cost per QALY within a NHS/PSS perspective), GS produced a 
greater health benefit and costed less than the other two interventions, and this result 
was not sensitive to a change in the costing perspective.  
The treatment recommendation, however, did alter with capability wellbeing as an 
evaluative space.  When outcomes moved from a health focus (QALYs) to a broader 
measure of capability wellbeing (YFC), and compared to NHS/PSS costs, TAU became 
the optimal strategy for a WTP greater than £11,500 per additional YFC.  Broadening 
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the analysis for both costs (government) and outcomes (YFC) had the effect of 
maintaining TAU as the optimal strategy, but this time for a greater WTP per additional 
YFC (£23,500).  Therefore, it appears that the recommendation for treatment is 
sensitive to the choice of evaluative space. 
To explore the impact of changing the criteria for decision making from a health 
maximisation to the maximisation of sufficient capability, YSC were also estimated.  
With this analysis, TAU remained the optimal strategy for a WTP per additional YSC 
above £19,700 from a NHS/PSS perspective and above £40,200 from a government 
perspective.   
(Table 5 about here) 
The principal finding from this study, therefore, is that broadening the evaluative space 
or altering the decision making rule has the potential of changing the treatment 
recommendation qualitatively. From the conventional cost per QALY health-focused 
evaluation, decision makers should be willing to fund GS.  From a broader capability 
wellbeing evaluative space, it is unlikely that decision makers would be willing to fund 
GS, not only because TAU may offer more value for money at potentially acceptable 
thresholds of willingness to pay per additional YFC or YSC, but mainly because the 
uncertainty associated with the decision to fund any intervention other than usual care 
is prohibitive enough for rational decision makers. 
This is the first study to explore the sufficient capability approach within an economic 
evaluation.  The wide range of primary data benefited the exploration of the impact of 
broader evaluative frameworks and alternative rules for decision making on treatment 
recommendation.  The study, however, had limitations.  Given that the purpose of the 
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pilot trial was to explore the feasibility of delivering psychological interventions in this 
clinical group, the economic evaluation relied on a modest sample size.  Since studies 
relying on modest sample sizes may lack external validity, the purpose of this paper was 
less to draw conclusions on the cost-effectiveness of the interventions, and more to use 
it as a case-study.   
A further limitation relates to the inherent difficulty in following-up heroin users.  For 
pragmatic reasons, a trade-off between exploring the short as well as the long-term 
impact of interventions while avoiding informative censoring was required by omitting 
intermediate follow-up periods.  In terms of costs, the resource use questionnaire 
provided information for the past 3 months of each follow-up period.  Thus, the absence 
of information between the 3rd and the 9th month of the trial was translated into the 
assumption that differences in costs between trial arms during this period remained 
constant.  Similarly, fluctuations in health-related quality of life and capability wellbeing 
between the 3rd and the 12th month could not be taken into consideration.   
Another limitation concerns the fidelity of interventions as participants failed to attend 
the required number of sessions.  Given that neither intervention was fully 
implemented, outcome differences represent the ‘noise’ between what happened and 
what was supposed to happen, especially in light of the modest sample size and baseline 
imbalances.  Furthermore, out of pocket costs were not collected due to the extra 
respondent burden imposed on this particular hard to reach study population.  
Information about the impact from the different addiction treatments on family and 
close friends was also not obtained due to practical difficulties in recruiting and 
retaining this group throughout the study duration. 
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Also, concerns have been expressed about the appropriateness of the EQ-5D in the fields 
of drug misuse [83, 85] and mental health [7, 86].   A study exploring the psychometric 
properties of the EQ-5D-3L in a heroin-dependent population found that nearly 91% 
and 82% of participants reported no problems in the self-care and mobility dimensions 
[87]. The proportion of participants with no problems in the remaining EQ-5D-3L 
dimensions ranged between 52% (pain/discomfort) and 62% (usual activities).  These 
findings appear to be consistent in this context.  A study exploring the measurement 
properties of the EQ-5D-5L and ICECAP-A, using the outcome data of this study, found 
that the proportion of heroin users in opioid substitution treatment reporting no 
problems in terms of self-care, mobility and usual activities was nearly 89%, 75%, and 
72% respectively [18].  The study found important differences in the sensitivity of the 
two measures to capture changes in clinical indicators, and therefore it is likely that 
these differences in psychometric performance drive the findings of this paper. 
There is also uncertainty with respect to the appropriate WTP threshold for a QALY in 
this context, as the conventional threshold, in theory, reflects the opportunity cost of 
spending from a fixed health budget.  There is a lack of evidence about the opportunity 
cost of spending when the QALYs fall outside the health context.  The UK Medical 
Research Council funded a review of the different methods for improving cross-sector 
comparisons using QALYs and other measures [88], and a research aiming to determine 
what society is willing to pay for a unit of full, and sufficient, capability has also recently 
been funded (see https://www.mrc.ac.uk/funding/how-we-fund-research/highlight-
notices/improving-cross-sector-comparisons-beyond-qaly/successfully-funded-
proposals/).  Until these results are known, one option, albeit somewhat arbitrary, is to 
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assume the same WTP threshold as that used for a QALY in health.  As more evidence is 
produced, future research can explore these assumptions.    
Finally, a new EQ-5D-5L value set for England has been developed since the conduct of 
this study.  This new value set is based on preferences elicited from a sample of 996 
adult members of the English general adult population using the time trade-off and 
discrete choice experiment methods [89].  This value set differs from the UK crosswalk 
value set in that only 5%, rather than nearly 27%, of health states are considered worse 
than death, namely having a health index score lower than zero.  However, given the 
large proportion of participants clustered at the high end of health-related quality of 
life, the choice between the two value sets is thought unlikely to have an appreciable 
impact on the findings of this study.  Further work could examine this issue. 
Decision making bodies, such as the UK National Institute for Health and Care 
Excellence, are currently assessing methods and adapting guidance to allow for the 
inclusion of non-health sector costs and outcomes [84, 90], and incorporate additional 
perspectives for analyses that go beyond the patient and the strictly defined health 
perspective [84]. Their operationalisation, however, remains unclear.  Capability 
wellbeing has so far been utilised alongside health-related measures of quality of life 
using the maximisation principle and not in terms of equalisation or sufficient capability 
as recommended [91].  Even as such, a parallel use of the ICECAP measures in economic 
evaluations alongside the commonly used instruments may act as a safety-pillar to base-
case analyses if results are verified [92, 93].  The two instruments, however, are quite 
distinct in what they measure and, therefore, the health effects of an intervention may 
not always be translated into a capability improvement, and similarly an absence of a 
health effect may not always imply the absence of important capability wellbeing gains.  
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This paper provides evidence that the two measures offer differing perspectives.  This, 
therefore, raises key questions concerning the implications of this result from a decision 
maker perspective. 
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Table 1. Health-related categories of resource use and associated unit costs (£, 
2012/2013 prices) 
Unit Cost* Source 
Primary care 
GP (per consultation) 41 PSSRU [44] 
GP (per telephone consultation lasting 7.1 minutes) 25 Ibid. 
Dentist (per consultation) 116 NHS Reference Cost [45] 
Community Pharmacist (per hour of patient-related 
activities) 64 PSSRU [44] 
Outpatient care 
Accident and emergency (A&E) visit  117 NHS Reference Cost [45] 
Hospital outpatient visit 135 PSSRU [44] 
Psychiatric outpatient visit Ɨ  100 Ibid. 
Inpatient care 
Inpatient stay 369ǂ   PSSRU [43] 
Drug/ Alcohol rehabilitation-related stay 326 NHS Reference Cost [45] 
Community care 
Mental health centre (per contact) ‡ 117 Ibid. 
Drug team (per community contact) 104 Ibid. 
Alcohol team (per community contact) 119 Ibid. 
Individual counselling (per hour of client contact) 63 PSSRU [44] 
Group counselling (per consultation) 58 Ibid. 
Mental health team (per hour with a team member) 36 Ibid. 
Psychologist (per hour of client contact) 134 Ibid. 
Nursing services (per hour of patient-related work) 50 Ibid. 
Social worker (per hour of patient-related work) 55 Ibid. 
Physiotherapist (per hour of patient contact) 30 Ibid. 
Home care worker (per hour weekday) 24 Ibid. 
Outreach worker (per hour of patient contact) 49 Ibid. 
Contact with a charitable organisation; Drug 
treatment day centre; Educational classes (drug or 
alcohol related); Other drug services (per user 
session)† 
38 
Ibid. 
* Costs involving duration of contact with health professionals were adjusted to the duration 
reported by participants 
Ɨ Excluding elderly people 
ǂ Inflated using the UK Hospital and Community Health Services pay and prices index [94] 
‡ Excluding inpatient services, services for children and adolescents and secure mental health 
services. Costs have been calculated based on the weighted average cost of services and the 
proportion of patients (activity) in each group 
† These are commissioned and run by third sector or charitable organisations. Therefore, there is a 
cost to the NHS, although lower than a contact with a drug team, which is more qualified. In the 
absence of a robust estimate, and given that many participants receive mental health-related 
medication, a cost of local authority social services day care for people with mental health 
problems was assumed  
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Table 2. Other resource use categories and their unit costs (£, 2012/2013 prices) 
Unit Cost Source 
Criminal justice 
Contacts with police* 226 Metropolitan Police [80] 
Psychiatric assessment while in prison or 
custody Ɨ 
195 NHS Reference Cost [45] 
Criminal and civil court appearance ǂ 754 Harries [47] 
Night in a police cell or prison  95 Ministry of Justice ([49] 
Supported accommodation (per day) 
Living in a hostel 16 Shelter [52] 
Living in a supported lodging 22 Bristol City Council [53] 
State benefits (per day) 
Income support (≥ 25 years old 
participants) 
10 
Department of Work and 
Pensions [50] 
Income support plus disability premium 4 Ibid. 
Income support plus severe disability 
premium 
9 Ibid. 
Jobseeker's allowance 10 Ibid. 
Disability working allowance 12 Ibid. 
Disability working allowance (care 
component) 
7 Ibid. 
Disability working allowance (mobility 
component) 
5 Ibid. 
Attendance allowance 9 Ibid. 
Statutory sick pay 12 Ibid. 
Housing benefit 13 Ibid. 
Council tax benefit 2 Ibid. 
State retirement pension 13 Ibid. 
Child benefit 3 Ibid. 
Family credit 2 Ibid. 
* Cost of £183.84 in 2005 was inflated to 2012/13 using inflation price indices from the Office for 
National Statistics [95] 
Ɨ Criminal Justice Liaison Services, Adult and Elderly  
ǂ Assuming all cases took place in a Magistrates' court. 1997/98 cost of £550 was inflated to 
2012/13 using inflation price indices from the Office for National Statistics [95] 
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Table 3. Mean per-client costs over the 12-month follow-up period (£, 2012/13 prices) 
Cost categories TAU (n = 30) B-SBNT (n = 26) GS (n = 27) 
Difference  
(B-SBNT minus TAU) 
Difference  
(GS minus TAU) 
Raw Mean (SE) Raw Mean (SE) Raw Mean (SE) Adjusted Mean* (95% CIs) Adjusted Mean* (95% CIs) 
NHS/PSS perspective 
Intervention 14 (2) 133 (6) 131 (4) 119 (107, 131) 117 (105, 129) 
Inpatient care 41 (28) 53 (51) 14 (14) 12 (-103, 128) -27 (-90, 36) 
Outpatient care 236 (85) 119 (69) 75 (31) -100 (-332, 132) -167 (-340, 7) 
Primary care 675 (153) 988 (222) 785 (147) 198 (-263, 659) 51 (-361, 462) 
Community care 1,508 (214) 1,816 (341) 1,376 (299) 317 (-473, 1,106) -37 (-757, 683) 
Medication 676 (165) 637 (125) 476 (34) 56 (-193, 305) -74 (-160, 12) 
Total NHS/PSS costs 3,149 (381) 3,747 (448) 2,856 (390) 420 (-334, 1,175) -198 (-955, 559) 
Additional cost components of governmental perspective 
Accommodation 197 (127) 173 (159) 60 (42) -37 (-250, 176) -147 (-363, 69) 
State benefits 3,293 (338) 3,099 (389) 3,049 (385) -192 (-1,056, 671) -102 (-822, 619) 
Criminal justice 508 (319) 374 (223) 303 (264) -134 (-870, 602) -204 (-1,044, 636) 
Total government costs 7,148 (652) 7,393 (776) 6,268 (682) 443 (-1,044, 1,931) -405 (-1,905, 1,094) 
TAU: Treatment as usual; B-SBNT: Brief social behaviour and network therapy; GS: Goal setting; SE: Standard error; CIs: Confidence intervals; NHS: National 
health service; PSS: Personal social services 
* Adjusted for baseline differences in the same cost category.  For individual cost components, a linear regression with robust standard errors based on 
Huber-White sandwich estimators was performed.  For total costs, a robust regression using iteratively reweighted least squares was performed 
 
 
 
 
 
 
27 
 
Table 4. Mean per-client outcomes over the 12-month follow-up period 
Outcomes  
(Evaluative space) 
TAU (n = 30) B-SBNT (n = 26) GS (n = 27) 
Difference  
(B-SBNT minus TAU) 
Difference  
(GS minus TAU) 
Raw Mean (SE) Raw Mean (SE) Raw Mean (SE) Adjusted Mean* (95% CIs) Adjusted Mean* (95% CIs) 
Baseline index scores 
EQ-5D-5L  
(Health) 0.769 (0.040) 0.684 (0.056) 0.720 (0.053) -0.067 (-0.192, 0.057) -0.030 (-0.153, 0.093) 
ICECAP-A  
(Full capability) 0.694 (0.033) 0.610 (0.041) 0.677 (0.033) -0.083 (-0.189, 0.024) -0.025 (-0.131, 0.081) 
ICECAP-A  
(Sufficient capability) 0.775 (0.034) 0.690 (0.044) 0.774 (0.035) -0.082 (-0.193, 0.028) -0.006 (-0.116, 0.103) 
Outcomes at the end of the trial 
QALYs  
(Health) 0.813 (0.037) 0.730 (0.057) 0.812 (0.046) 0.010 (-0.091, 0.112) 0.037 (-0.059, 0.133) 
YFC  
(Full capability) 0.770 (0.029) 0.673 (0.044) 0.738 (0.033) -0.038 (-0.117, 0.041) -0.017 (-0.091, 0.056) 
YSC  
(Sufficient capability) 0.853 (0.030) 0.759 (0.048) 0.836 (0.036) -0.028 (-0.110, 0.054) -0.010 (-0.088, 0.067) 
TAU: Treatment as usual; B-SBNT: Brief social behaviour and network therapy; GS: Goal setting; SE: Standard error; CIs: Confidence intervals; QALYs: 
Quality-adjusted life-years; YFC: Year of full capability equivalent; YSC: Year of sufficient capability equivalent 
* Adjusted for baseline differences in utility, capability-wellbeing or sufficient capability wellbeing  
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Table 5. Summary table of results 
Evaluative space 
(Decision making rule) 
Costing perspective 
NHS/PSS Government 
Health  
(Maximisation) 
GS is the optimal 
intervention for any WTP 
per QALY 
GS is the optimal 
intervention for any WTP 
per QALY 
Capability wellbeing 
(Maximisation) 
TAU is the optimal 
intervention for WTP ≥ 
£11,500 per YFC 
TAU is the optimal 
intervention for WTP ≥ 
£23,500 per YFC 
Capability wellbeing 
(Sufficiency) 
TAU is the optimal 
intervention for WTP ≥ 
£19,700 per YSC 
TAU is the optimal 
intervention for WTP ≥ 
£40,200 per YSC 
NHS: National health service; PSS: Personal social services; TAU: Treatment as usual; GS: 
Goal setting; QALY: Quality-adjusted life-year; YFC: Year of full capability equivalent; YSC: 
Year of sufficient capability equivalent; WTP: Willingness to pay 
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Appendix 1. The ICECAP-A questionnaire [14]1  
 
 
 
 
 
 
 
 
 
                                                          
1 Reproduced with permission of the authors 
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